Qure.ai qER
by Qure.ai
qER is Qure.ai's emergency-care AI suite for analyzing medical images, including head CT scans and chest X-rays. It flags suspected abnormalities and supports triage and workflow prioritization for clinicians.
Why Abandoned
Qure.ai currently lists qER on its official product website, and its emergency-care imaging products remain represented in the company's current portfolio. No shutdown or acquisition of the product was identified.
🩺 Health Signals
- HTTP Status
- 200
- Response
- —
- SSL
- —
- Confidence
- 90%
- Domain expires
- —
- Last content change
- —
- Last tweet
- —
- API status
- —
📅 Timeline
Qure.ai founded
Prashant Warier and Pooja Rao founded Qure.ai to develop artificial-intelligence systems for medical imaging.
qER receives FDA clearance for intracranial hemorrhage triage
Qure.ai announced U.S. FDA 510(k) clearance for qER's emergency-room head CT triage capability for suspected intracranial hemorrhage.
Qure.ai raises $40 million
Qure.ai announced a $40 million financing round led by Novo Holdings and HealthQuad, with participation from existing investor MassMutual Ventures.
Qure.ai raises $65 million
Qure.ai announced a $65 million Series D financing round led by Lightspeed and 360 ONE Asset, with participation from Merck Global Health Innovation Fund and Kae Capital.
🔄 Alternatives to Qure.ai qER
Akkio
🟢ActiveAkkio is an AI analytics platform for agencies and business teams. It supports data preparation, predictive modeling, forecasting, reporting, and generative analysis through no-code workflows and conversational interfaces.
Hugging Face
🟢ActiveThe GitHub of machine learning — hosting models, datasets, and AI applications.
Obviously AI
🟢ActiveObviously AI is a no-code predictive analytics platform for building machine-learning models from tabular business data. It supports prediction, model explanation, deployment, and integration workflows.
🪦 Other dead Healthcare tools
Kheiron Mia
🟡Acquired / MergedMia is Kheiron Medical Technologies’ artificial intelligence platform for breast-screening mammography. It supports radiologists by analyzing mammograms and identifying cases that may warrant further review.
MaxQ AI ACCIPIO
🟠Possibly DeadACCIPIO was MaxQ AI's clinical AI platform for analyzing non-contrast head CT scans and prioritizing suspected intracranial hemorrhage cases for radiologist review. It was a triage aid, not a standalone diagnosis system.
Arterys Cardio AI
🟡Acquired / MergedCloud-based cardiac MRI analysis software that used machine learning to assist clinicians with image segmentation, ventricular measurements, and cardiac function assessment. Tempus acquired Arterys in 2022.
Zebra Medical Vision Imaging Analytics
🟡Acquired / MergedAI-based medical imaging analytics developed by Zebra Medical Vision to help identify findings in radiology scans. Nanox acquired Zebra in 2021 and incorporated its software into the Nanox.AI portfolio.
❓ Frequently Asked Questions
What is Qure.ai qER?
Qure.ai qER is an AI suite for emergency-care medical imaging. It analyzes scans such as non-contrast head CTs and chest X-rays, flags suspected abnormalities, and helps clinicians prioritize urgent cases.
How does Qure.ai qER support emergency radiology workflows?
qER processes eligible medical images and generates alerts or findings that can help radiology and emergency teams prioritize examinations requiring rapid review. It is intended to support, not replace, clinician interpretation.
What medical images can Qure.ai qER analyze?
The qER portfolio covers emergency imaging use cases involving non-contrast head CT and chest X-ray. Exact capabilities and regulatory clearances vary by module, indication, and country.
Is Qure.ai qER FDA cleared?
Qure.ai announced U.S. FDA 510(k) clearance in 2020 for qER's head CT triage capability for suspected intracranial hemorrhage. Buyers should verify the clearance and intended use of each specific module before deployment.
Is Qure.ai qER still available?
Yes. Qure.ai continues to list qER on its official website as part of its emergency-care product portfolio. Its availability, approved indications, and integrations may differ by market.